Central Precocious Puberty clinical trials at UCSF
1 research study open to eligible people
Central precocious puberty is the early onset of puberty in children. UCSF is conducting trials on Debio 4326 to study its effects and safety on young patients. This research is important for understanding treatment options for children affected by early puberty.
Showing trials for
Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)
open to eligible people ages 5-8
The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52 weeks after the first Debio 4326 injection in pediatric participants with central precocious puberty (CPP).
San Francisco, California and other locations
Last updated: